Plasminogen activator inhibitor-1 impairs alveolar epithelial repair by binding to vitronectin.
The pathogenesis of pulmonary fibrosis is thought to involve alveolar epithelial injury that, when successfully repaired, can limit subsequent scarring. The plasminogen system participates in this process with the balance between urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor-1 (PAI-1) being a critical determinant of the extent of collagen accumulation that follows lung injury. Because the plasminogen system is known to influence the rate of migration of epithelial cells, including keratinocytes and bronchial epithelial cells, we hypothesized that the balance of uPA and PAI-1 would affect the efficiency of alveolar epithelial cell (AEC) wound repair. Using an in vitro model of AEC wounding, we show that the efficiency of repair is adversely affected by a deficiency in uPA or by the exogenous administration of PAI-1. By using PAI-1 variants and AEC from mice transgenically deficient in vitronectin (Vn), we demonstrate that the PAI-1 effect requires its Vn-binding activity. Furthermore, we have found that cell motility is enhanced by the availability of Vn in the matrix and that the AEC-Vn interaction is mediated, in part, by the alpha(v)beta(1) integrin. The significant effect of uPA and PAI-1 on epithelial repair suggests a mechanism by which the plasminogen system may modulate pulmonary fibrosis.
Lazar
Michael H
MH
Department of Internal Medicine, University of Michigan Medical Center, 1150 West Medical Center Drive, 6301 MSRB III, Ann Arbor, MI 48109-0642, USA.
Christensen
Paul J
PJ
Du
Ming
M
Yu
Bi
B
Subbotina
Natalya M
NM
Hanson
Kerstin E
KE
Hansen
Jean M
JM
White
Eric S
ES
Simon
Richard H
RH
Sisson
Thomas H
TH
D000818:Animals; D001761:Bleomycin / Q000031:analogs & derivatives* / Q000494:pharmacology; D045744:Cell Line, Tumor; D002465:Cell Movement; D003094:Collagen / Q000378:metabolism; D006801:Humans; D051379:Mice; D018345:Mice, Knockout; D017395:Plasminogen Activator Inhibitor 1 / Q000494:pharmacology*; D011485:Protein Binding; D011650:Pulmonary Alveoli / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology*; D011658:Pulmonary Fibrosis / Q000139:chemically induced / Q000378:metabolism; D014568:Urokinase-Type Plasminogen Activator / Q000494:pharmacology; D019096:Vitronectin / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*; D014945:Wound Healing / Q000187:drug effects*
D017395:Plasminogen Activator Inhibitor 1; D019096:Vitronectin; D001761:Bleomycin; C025703:bleomycetin; D003094:Collagen; D014568:Urokinase-Type Plasminogen Activator